TEGAFIRI is an effective alternative regimen for the management of recurrent or metastatic colorectal cancer

Hsu,Tzu‑Chi

doi:10.3892/ol.2015.2855

TEGAFIRI is an effective alternative regimen for the management of recurrent or metastatic colorectal cancer

Authors:
- Tzu‑Chi Hsu
View Affiliations

Affiliations: Department of Surgery, Mackay Memorial Hospital, Zhongshan, Taipei 104, Taiwan, R.O.C.
Published online on: January 7, 2015 https://doi.org/10.3892/ol.2015.2855
Pages: 1059-1064
Copyright: © Hsu . This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

At present, the global incidence of colorectal cancer is increasing, with numerous individuals succumbing to the disease. The standard treatment strategy for colorectal cancer is curative resection. However, a cure is rarely achieved for metastatic colorectal cancer. Currently, chemotherapy is the main treatment for metastatic and recurrent colorectal cancer. The majority of metastases or recurrences have been found to respond well to chemotherapy. The present study evaluated the response rates of recurrent or metastatic colorectal cancer patients treated with a combination chemotherapy of irinotecan and oral uracil‑tegafur (UFUR). In the pilot study, 33 patients with metastatic or recurrent colorectal cancer were treated with different regimens of irinotecan and UFUR with or without leucovorin; however, irinotecan (150 mg/m2 every two weeks) with continuous UFUR and leucovorin without interruption resulted in improved survival compared with the other regimens evaluated and, thus, was employed for the present study of 113 patients. The patients that received irinotecan with UFUR and leucovorin without interruption exhibited similar efficacy in terms of overall survival and response rate to that of the pilot study. In addition, the incidences of diarrhea, alopecia and hematologic toxicity were acceptable, which was in agreement with the results of the pilot study. Therefore, combination chemotherapy with irinotecan, oral UFUR and leucovorin appears to be a satisfactory treatment strategy for recurrent or metastatic colorectal cancer.

View Figures

View References

1	Yeh KH, Cheng AL, Lin MT, et al: A phase II study of weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin (HDFL) in the treatment of recurrent or metastatic colorectal cancers. Anticancer Res. 17:3867–3871. 1997.
2	Mermershtain W, Lavrenkov K and Cohen Y: Phase II study of weekly high-dose fluorouracil in previously treated patients with metastatic colorectal cancer. J Chemother. 12:183–185. 2000. View Article : Google Scholar : PubMed/NCBI
3	Cunningham D, Pyrhönen S, James RD, et al: Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patient with metastatic colorectal cancer. Lancet. 352:1413–1418. 1998. View Article : Google Scholar : PubMed/NCBI
4	Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicenter randomized trial. Lancet. 355:1041–1047. 2000. View Article : Google Scholar : PubMed/NCBI
5	Rothenberg ML, Cox JV, Devore RF, et al: A multicenter phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer. 85:786–795. 1999. View Article : Google Scholar : PubMed/NCBI
6	Van Cutsem E, Pozzo C, Starkhammar H, et al: A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer. Ann Oncol. 9:1199–1204. 1998. View Article : Google Scholar : PubMed/NCBI
7	Ota K, Taguchi T and Kimura K: Report on nationwide-pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol. 22:333–338. 1988. View Article : Google Scholar
8	Malet-Martino M and Martino R: Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. Oncologist. 7:288–323. 2002. View Article : Google Scholar : PubMed/NCBI
9	Kusunoki M, Yanagi H, Noda M, et al: Results of pharmacokinetic modulating chemotherapy in combination with hepatic arterial 5-fluorouracil infusion and oral UFT after resection of hepatic colorectal metastases. Cancer. 89:1228–1235. 2000. View Article : Google Scholar : PubMed/NCBI
10	Mackay HJ, Hill M, Twelves C, et al: A phase I/II study of oral uracil/tegafur (UFT), leucovorin, and irinotecan in patients with advanced colorectal cancer. Ann Oncol. 14:1264–1269. 2003. View Article : Google Scholar : PubMed/NCBI
11	Mibu R, Tanaka S, Futami K, et al: Phase I/II study of irinotecan and UFT for advanced or metastatic colorectal cancer. Anticancer Res. 27:2673–2678. 2007.PubMed/NCBI
12	Bajetta E, Bartolomeo MD, Buzzoni R, et al: Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patient: results of randomized phase II study. Br J Cancer. 96:439–444. 2007. View Article : Google Scholar : PubMed/NCBI
13	Delord JP, Bennouna J, Artru P, et al: Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer. Br J Cancer. 97:297–301. 2007. View Article : Google Scholar : PubMed/NCBI
14	Ogata Y, Mori S, Ishibashi Y, et al: Metronomic chemotherapy using weekly low-dosage CPT-11 and UFT as postoperative adjuvant therapy in colorectal cancer at high risk to recurrence. J Exp Clin Cancer Res. 26:475–482. 2007.
15	Hsu TC: Combination chemotherapy with irinotecan and oral uracil-tegafur for recurrent or metastatic colorectal cancer - results of different regimens. J Chinese Oncol Soc. 25:254–261. 2009.(In Chinese).
16	Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
17	Schag CC, Heinrich RL and Ganz PA: Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncology. 2:187–193. 1984.
18	Dukes CE: The surgical pathology of rectal cancer. J Clin Pathol. 2:95–98. 1949. View Article : Google Scholar : PubMed/NCBI
19	Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar
20	Cancer Therapy Evaluation Program. Common Toxicity Criteria, Version 2.0. April 30–1999, http://prevention.cancer.gov/files/clinical-trials/common-toxicity-criteria.pdf. Accessed November 22, 2014
21	Jemal A, Tiwari RC, Murray T, et al: American Cancer Society: Cancer statistics, 2004. CA Cancer J Clin. 54:8–29. 2004. View Article : Google Scholar : PubMed/NCBI
22	Parkin DM, Pisani P and Ferlay J: Global cancer statistics. CA Cancer J Clin. 49:33–64. 1999. View Article : Google Scholar : PubMed/NCBI
23	Colorectal Cancer. Estimated Incidence, Mortality and Prevalence Worldwide in 2012. GLOBOCAN. 2012, http://globocan.iarc.fr/old/FactSheets/cancers/colorectal-new.asp. Accessed November 22, 2014
24	Colorectal Cancer Facts & Figures 2014–2016. American Cancer Society; 2014, http://www.cancer.org/acs/groups/content/documents/document/acspc-042280.pdf. Accessed November 22, 2014
25	DeVita VT Jr, Hellman S and Rosenberg SA: Cancer Principles and Practice of Oncology. 5th edition. Lippincott-Raven; Philadelphia, PA: pp. 437–452. 1997
26	Fujii S, Kitano S, Ikenaka K and Shirasaka T: Studies on coadministration of uracil or cytosine on antitumor activity of FT-207 or 5-FU derivatives. Jpn J Cancer Chemother. 6:377–384. 1979.
27	Douillard JY, Hoff P, Skillings JR, et al: Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 20:3605–3616. 2002. View Article : Google Scholar : PubMed/NCBI
28	Hoff PM, Lassere Y and Pazdur R: Tegafur/uracil + calcium folinate in colorectal cancer: double modulation of fluorouracil. Drugs. 58:77–83. 1999. View Article : Google Scholar
29	Köhne CH and Peters GJ: UFT: mechanism of drug action. Oncology (Williston Park). 14(10 Suppl 9): 13–18. 2000.
30	Pazdur R, Hoff PM, Medgyesy D, et al: The oral fluorouracil prodrugs. Oncology (Williston Park). 12(10 Suppl 7): 48–51. 1998.
31	Carmichael J, Popiela T, Radstone D, et al: Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 20:3617–3627. 2002. View Article : Google Scholar : PubMed/NCBI
32	Kusunoki M, Yanagi H, Noda M and Yamamura T: The usefulness of pharmacokinetic modulating chemotherapy (UFT plus 5FU) in the treatment of unresectable colorectal carcinomas. Oncol Rep. 6:547–552. 1999.PubMed/NCBI
33	Lin JK, Wang WS, Hsieh RK, et al: Phase II study of oral tegafur-uracil and folinic acid as first-line therapy for metastatic colorectal cancer: Taiwan experience. Jpn J Clin Oncol. 30:510–514. 2000. View Article : Google Scholar
34	Hsiao SC, Lin JF, Chuang MT, Lee YA and Wu DL: Retrospectively comparative evaluation of the first- and second-line chemotherapy with campto and oxaliplatin combined with oral tegafur/uracil (UFT)/leucovorin (LV) in patients with metastatic colorectal cancer. Int Surg. 94:298–303. 2009.